Government-Owned Inventions; Availability for Licensing, 11235 [2017-03306]

Download as PDF sradovich on DSK3GMQ082PROD with NOTICES Federal Register / Vol. 82, No. 33 / Tuesday, February 21, 2017 / Notices Contact Person: Reigh-Yi Lin, Ph.D., Scientific Review Officer, Center for Scientific Review, 6701 Rockledge Drive, Bethesda, MD 20892, 301–827–6009, lin.reigh-yi@nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR 16– 366—Dual Purpose with Dual Benefit: Research in Biomedicine and Agriculture. Date: March 21, 2017. Time: 8:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Tera Bounds, DVM, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3214, MSC 7808, Bethesda, MD 20892, 301–435– 2306, boundst@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Fellowships: Risk, Prevention and Health Behavior Overflow. Date: March 21, 2017. Time: 9:00 a.m. to 1:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Stacey C. FitzSimmons, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3114, MSC 7808, Bethesda, MD 20892, (301) 451– 9956, fitzsimmonss@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Urology and Urogynecology Small Business Applications. Date: March 21, 2017. Time: 9:00 a.m. to 12:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Ganesan Ramesh, Ph.D., Center for Scientific Review, National Institutes of Health, 6701 Rockledge Dr., Room 2182, MSC 7818, Bethesda, MD 20892, ganesan.ramesh@nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Topics in drug discovery and clinical field studies. Date: March 21, 2017. Time: 10:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Liangbiao Zheng, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3202, MSC 7808, Bethesda, MD 20892, 301–996– 5819, zhengli@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, VerDate Sep<11>2014 17:15 Feb 17, 2017 Jkt 241001 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: February 14, 2017. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2017–03281 Filed 2–17–17; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The inventions listed below are owned by an agency of the U.S. Government. FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained by emailing the indicated licensing contact at the National Heart, Lung, and Blood, Office of Technology Transfer and Development Office of Technology Transfer, 31 Center Drive, Room 4A29, MSC2479, Bethesda, MD 20892–2479; telephone: 301–402–5579. A signed Confidential Disclosure Agreement may be required to receive any unpublished information. SUPPLEMENTARY INFORMATION: The following inventions are available for licensing in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Technology description follows. SUMMARY: Methods for Improving Drug Delivery to the Central Nervous System The invention relates to the uses of the tricyclic antidepressant amitriptyline, its bioactive metabolites, and other LPA1R activators to improve the bioavailability and delivery of therapeutics to the central nervous system. This invention demonstrates that amitriptyline and other agents selectively decrease P-glycoprotein (Pgp) transport activity by ligand activation of lysophosphatidic acid 1 receptor (LPA1R) at the blood-brain barrier. P-gp is an effective target for increasing drug delivery to the brain (CNS) for two major reasons: (1) Its substrates include a large portion of onthe-market drugs, including chemotherapeutics, and (2) its directionality results in a net efflux of drugs from the brain. Additionally, specifically targeting P-gp through PO 00000 Frm 00065 Fmt 4703 Sfmt 4703 11235 LPA1R activation bypasses the clinical challenges resulting from the toxicity of substrate inhibitors of P-gp. This invention describes the inhibition of drug efflux by P-gp transport; thus, coadministration of therapeutics with amitriptyline and other LPA1R activators provides a method for increasing drug delivery to the CNS, and improving overall drug efficacy. Moreover, drug delivery to other barrier tissues will also be enhanced where a similar LPA1R–P-gp activity relationship exists. Potential Commercial Applications: • Drug Delivery to the CNS. • Co-administration of therapeutics. • Blood-brain-barrier permeability. Development Stage: • Early stage. Inventors: Ronald Cannon and David Banks (NIEHS). Publications: • Cannon et al., Neurosci Lett. 2017 Feb 3;639:103–113 doi: 10.1016/ j.neulet.2016.12.049. • Mesev, et al., Mol Pharmacol. 2017 Jan 24. pii: mol.116.107169. doi: 10.1124/mol.116.107169. • More, et al., J Cereb Blood Flow Metab. 2016 May 18. pii: 0271678X16650216. • Miller, et. al, Curr Pharm Des. 2014;20(10):1463–71. Review. • Cartwright, et al., J Cereb Blood Flow Metab. 2013 Mar;33(3):381–8. doi: 10.1038/jcbfm.2012.174. Intellectual Property: HHS Reference No. E–179–2065/0 and/1; U.S. Provisional Patent Applications 62/ 332,888 filed May 6, 2016, and 62/ 453,718 filed February 2, 2017, respectively. Licensing Contact: Michael Shmilovich, Esq., CLP; 301–435–5019; shmilovm@mail.nih.gov. Dated: February 10, 2017. Michael Shmilovich, Senior Licensing and Patenting Manager, National Heart, Lung, and Blood Institute, Office of Technology Transfer and Development. [FR Doc. 2017–03306 Filed 2–17–17; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. E:\FR\FM\21FEN1.SGM 21FEN1

Agencies

[Federal Register Volume 82, Number 33 (Tuesday, February 21, 2017)]
[Notices]
[Page 11235]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-03306]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government.

FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained 
by emailing the indicated licensing contact at the National Heart, 
Lung, and Blood, Office of Technology Transfer and Development Office 
of Technology Transfer, 31 Center Drive, Room 4A29, MSC2479, Bethesda, 
MD 20892-2479; telephone: 301-402-5579. A signed Confidential 
Disclosure Agreement may be required to receive any unpublished 
information.

SUPPLEMENTARY INFORMATION: The following inventions are available for 
licensing in accordance with 35 U.S.C. 209 and 37 CFR part 404 to 
achieve expeditious commercialization of results of federally-funded 
research and development. Technology description follows.

Methods for Improving Drug Delivery to the Central Nervous System

    The invention relates to the uses of the tricyclic antidepressant 
amitriptyline, its bioactive metabolites, and other LPA1R activators to 
improve the bioavailability and delivery of therapeutics to the central 
nervous system. This invention demonstrates that amitriptyline and 
other agents selectively decrease P-glycoprotein (P-gp) transport 
activity by ligand activation of lysophosphatidic acid 1 receptor 
(LPA1R) at the blood-brain barrier. P-gp is an effective target for 
increasing drug delivery to the brain (CNS) for two major reasons: (1) 
Its substrates include a large portion of on-the-market drugs, 
including chemotherapeutics, and (2) its directionality results in a 
net efflux of drugs from the brain. Additionally, specifically 
targeting P-gp through LPA1R activation bypasses the clinical 
challenges resulting from the toxicity of substrate inhibitors of P-gp. 
This invention describes the inhibition of drug efflux by P-gp 
transport; thus, co-administration of therapeutics with amitriptyline 
and other LPA1R activators provides a method for increasing drug 
delivery to the CNS, and improving overall drug efficacy. Moreover, 
drug delivery to other barrier tissues will also be enhanced where a 
similar LPA1R-P-gp activity relationship exists.
    Potential Commercial Applications:
     Drug Delivery to the CNS.
     Co-administration of therapeutics.
     Blood-brain-barrier permeability.
    Development Stage:
     Early stage.
    Inventors: Ronald Cannon and David Banks (NIEHS).
    Publications:
     Cannon et al., Neurosci Lett. 2017 Feb 3;639:103-113 doi: 
10.1016/j.neulet.2016.12.049.
     Mesev, et al., Mol Pharmacol. 2017 Jan 24. pii: 
mol.116.107169. doi: 10.1124/mol.116.107169.
     More, et al., J Cereb Blood Flow Metab. 2016 May 18. pii: 
0271678X16650216.
     Miller, et. al, Curr Pharm Des. 2014;20(10):1463-71. 
Review.
     Cartwright, et al., J Cereb Blood Flow Metab. 2013 
Mar;33(3):381-8. doi: 10.1038/jcbfm.2012.174.
    Intellectual Property: HHS Reference No. E-179-2065/0 and/1; U.S. 
Provisional Patent Applications 62/332,888 filed May 6, 2016, and 62/
453,718 filed February 2, 2017, respectively.
    Licensing Contact: Michael Shmilovich, Esq., CLP; 301-435-5019; 
shmilovm@mail.nih.gov.

    Dated: February 10, 2017.
Michael Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood 
Institute, Office of Technology Transfer and Development.
[FR Doc. 2017-03306 Filed 2-17-17; 8:45 am]
 BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.